Aardvark Therapeutics, INC. (AARD) — SEC Filings

Q: What are the key financial highlights for Aardvark Therapeutics, INC.?

Key financial highlights for Aardvark Therapeutics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Aardvark Therapeutics, INC.?

Key executives at Aardvark Therapeutics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Aardvark Therapeutics, INC. stock?

Risk factors for Aardvark Therapeutics, INC. (AARD) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Aardvark Therapeutics, INC.?

Forward-looking statements and predictions from Aardvark Therapeutics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Aardvark Therapeutics, INC.. Recent EFFECT filing on Apr 6, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Aardvark Therapeutics, INC. on SEC EDGAR

Overview

Aardvark Therapeutics, INC. (AARD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 6, 2026: Aardvark Therapeutics, Inc. (CIK: 0001774857) filed an EFFECT form, indicating the effectiveness of a registration statement, on April 6, 2026. The effectiveness date is noted as April 3, 2026. The company is located at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA 92122.

Sentiment Summary

Across 15 filings, the sentiment breakdown is: 1 bearish, 14 neutral. The dominant filing sentiment for Aardvark Therapeutics, INC. is neutral.

Filing Type Overview

Aardvark Therapeutics, INC. (AARD) has filed 1 EFFECT, 2 10-K, 9 8-K, 1 10-Q, 1 S-1/A, 1 S-1 with the SEC between Jan 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (15)

Aardvark Therapeutics Registration Statement Effective — EFFECT · Apr 6, 2026 Risk: medium
Aardvark Therapeutics, Inc. (CIK: 0001774857) filed an EFFECT form, indicating the effectiveness of a registration statement, on April 6, 2026. The effectivenes
Aardvark Pauses Key Trials Amid Cardiac Safety Concerns — 10-K · Mar 23, 2026 Risk: high
Aardvark Therapeutics, Inc. (AARD) is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics for metabolic diseases.
Aardvark Therapeutics Files 8-K — 8-K · Dec 10, 2025 Risk: low
On December 10, 2025, Aardvark Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," ind
Aardvark Therapeutics Files 8-K on Financials — 8-K · Nov 13, 2025 Risk: low
Aardvark Therapeutics, Inc. filed an 8-K on November 13, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements a
Aardvark Therapeutics Files 8-K — 8-K · Nov 6, 2025 Risk: low
Aardvark Therapeutics, Inc. filed an 8-K on November 6, 2025, reporting an event on November 5, 2025. The filing pertains to "Other Events" and "Financial State
8-K Filing — 8-K · Nov 4, 2025
Aardvark Therapeutics Files 8-K — 8-K · Oct 9, 2025 Risk: low
Aardvark Therapeutics, Inc. filed an 8-K on October 9, 2025, reporting an event on October 8, 2025. The filing indicates "Other Events" and "Financial Statement
8-K Filing — 8-K · Sep 3, 2025
Aardvark Therapeutics Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
Aardvark Therapeutics, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing includes financial state
Aardvark Therapeutics Files 8-K — 8-K · Aug 12, 2025 Risk: low
On August 12, 2025, Aardvark Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with
Aardvark Therapeutics Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: low
Aardvark Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company's business address is located at 4370 La Jolla Village
10-K Filing — 10-K · Mar 31, 2025
Aardvark Therapeutics Files 8-K with Corporate Updates — 8-K · Feb 14, 2025 Risk: low
Aardvark Therapeutics, Inc. filed an 8-K on February 14, 2025, reporting amendments to its articles of incorporation or bylaws, other events, and financial stat
Aardvark Therapeutics Files IPO Amendment — S-1/A · Feb 6, 2025 Risk: medium
Aardvark Therapeutics, Inc. filed an S-1/A amendment on February 6, 2025, for its initial public offering. The company, located at 4370 La Jolla Village Drive,
Aardvark Therapeutics Files S-1 for Potential Offering — S-1 · Jan 23, 2025 Risk: medium
Aardvark Therapeutics, Inc., incorporated in Delaware, filed an S-1 registration statement on January 23, 2025. The company, located at 4370 La Jolla Village Dr

Risk Profile

Risk Assessment: Of AARD's 12 recent filings, 1 were flagged as high-risk, 3 as medium-risk, and 8 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Aardvark Therapeutics, INC.'s most recent 10-K filing (Mar 23, 2026):

Revenue: N/A
Net Income: N/A
EPS: N/A
Debt-to-Equity: N/A
Cash Position: N/A
Operating Margin: N/A
Total Assets: N/A
Total Debt: N/A

Key Executives

Dr. Tien Lee
Dr. Manasi Jaiman
Nelson Sun
Tien-Li Lee, M.D.

Industry Context

The biopharmaceutical industry, particularly in the metabolic disease space, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Aardvark Therapeutics compete with both large, established pharmaceutical firms and smaller, innovative biotech startups. Recent trends show increasing investment in treatments for obesity and rare genetic disorders, driven by unmet medical needs and a growing understanding of disease mechanisms.

Top Tags

registration-statement (2) · sec-filing (2) · 8-k (2) · financial-reporting (2) · 8-K (2) · pharmaceuticals (2) · effectiveness (1) · Biopharmaceutical (1) · Clinical Trials (1) · Drug Development (1)

Key Numbers

File Number: 333-294537 — SEC registration file number
Aggregate market value of common equity held by non-affiliates: $162.9 million — As of June 30, 2025, based on a closing price of $13.52 per share.
Shares of common stock outstanding: 21,816,041 — As of February 28, 2026.
Total funds raised prior to IPO: $129.1 million — Supported by life sciences and institutional investors before February 2025 IPO.
Series C financing amount: $85.0 million — Led by Decheng prior to the IPO.
Mean decline in HQ-CT score: 9 points — In 7 subjects in Part 1 of ARD-101 Phase 2 trial at day 28.
Decrease in HQ-CT score: 8 points — In 4 subjects in Part 2 of ARD-101 Phase 2 trial at 28 days.
Target enrollment for HERO trial: 90 patients — Over 50% completed by January 2026.
Date of voluntary trial pause: February 27, 2026 — Due to reversible cardiac observations in a healthy volunteer study.
Year company founded: 2017 — By Dr. Tien Lee.
Month and year of IPO: February 2025 — Initial Public Offering.
SEC File Number: 001-42513 — Identifies the company's filing history with the SEC.
IRS Employer Identification No.: 821606367 — Company's tax identification number.
SIC Code: 2834 — Pharmaceutical Preparations industry
IRS Number: 82-1606367 — Company's Employer Identification Number.

Frequently Asked Questions

What are the latest SEC filings for Aardvark Therapeutics, INC. (AARD)?

Aardvark Therapeutics, INC. has 15 recent SEC filings from Jan 2025 to Apr 2026, including 9 8-K, 2 10-K, 1 EFFECT. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AARD filings?

Across 15 filings, the sentiment breakdown is: 1 bearish, 14 neutral. The dominant sentiment is neutral.

Where can I find Aardvark Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Aardvark Therapeutics, INC. (AARD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Aardvark Therapeutics, INC.?

Key financial highlights from Aardvark Therapeutics, INC.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for AARD?

The investment thesis for AARD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Aardvark Therapeutics, INC.?

Key executives identified across Aardvark Therapeutics, INC.'s filings include Dr. Tien Lee, Dr. Manasi Jaiman, Nelson Sun, Tien-Li Lee, M.D..

What are the main risk factors for Aardvark Therapeutics, INC. stock?

Of AARD's 12 assessed filings, 1 were flagged high-risk, 3 medium-risk, and 8 low-risk.

What are recent predictions and forward guidance from Aardvark Therapeutics, INC.?

Forward guidance and predictions for Aardvark Therapeutics, INC. are extracted from SEC filings as they are enriched.